With a positive phase 3 trial in hand, Japan’s Daiichi Sankyo plans to file its essential hypertension therapy esaxerenone in its home market.
A new test quickly shows if an antibiotic fights a given infection, which can reduce improperly prescribed antibiotics.
RBM is, above all, an opportunity to practice mindfulness in collecting clinical trial data within the site- and patient-centric environment.
J&J is now assessing what it will take to quell the FDA’s concerns about the safety of the IL-6 monoclonal antibody before deciding on a path forward.
In a first for the Big Pharma and as part of a new model, Pfizer is taking drugs from its shelves and licensing them to its startup, SpringWorks.
AbbVie joins forces with Bristol-Myers Squibb once again to test an experimental cancer drug with BMS' checkpoint inhibitor Opdivo.
Versartis’ somavaratan has failed to match Pfizer’s Genotropin in phase 3, wiping more than 80% off its stock price.
Nestlé is beating a retreat from topical dermatology drug R&D at the cost of up to 450 jobs and possibly a facility.
Andrew Witty jumped into biotech venture capital, Aerie poached another exec from Alcon, Roivant tapped Silicon Valley vet to run trial AI company.
In this week's EuroBiotech Report, phase 3 data send Bavarian Nordic and Nabriva in opposite directions, Immunocore raises $40 million and more.
In our EuroBiotech roundup this week, Autolus advances CAR-T trial, Cell Medica names CSO and AB Science suffers a regulatory setback.